At only $450mcap is Corbus Pharmaceuticals undervalued?
1) Corbus is different from other cannabis stocks as they are designing therapies around marijuana to treat fibrotic diseases. If these therapies work, some analysts put the value of their potential sales at
2BN a year.
2) At a small marketcap of $450m, Corbus could be a real untouched gem in the cannabis industry, compared to its competitors with
4BN+ marketcap.
3) After an agreement with Japananese Kaken Pharmaceutical, Corbus is on the way to receive an additional $173m upon achievement of various milestones
1) Corbus is different from other cannabis stocks as they are designing therapies around marijuana to treat fibrotic diseases. If these therapies work, some analysts put the value of their potential sales at
2BN a year.2) At a small marketcap of $450m, Corbus could be a real untouched gem in the cannabis industry, compared to its competitors with
4BN+ marketcap.3) After an agreement with Japananese Kaken Pharmaceutical, Corbus is on the way to receive an additional $173m upon achievement of various milestones
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.